Abstract
Over the past several years, research has indicated that an individuals genetic makeup strongly influences not only their likelihood of developing depression, but also whether or not they will respond well to a particular antidepressant treatment. Identifying those genes regulating susceptibility to depression will increase our understanding of disease pathophysiology and direct the development of treatments that correct underlying neurobiological pathology related to stress-related psychiatric illnesses. Pharmacologically, the identification of genes regulating treatment response can lead to the design of novel pharmacological treatments and allow for more individualized, rational and successful drug treatments. Unfortunately, complex environmental and genetic mechanisms at play in depression and drug response make the discovery of susceptibility genes in humans quite difficult. Animal models may provide a more desirable system in which to discover susceptibility genes because environmental factors and tests can be regulated and more informative genetic methods can be used. Furthermore, a unique genetic opportunity exists with animal models of depression and antidepressant response because several rodent strains have been identified, or selectively bred, that display exaggerated depressive phenotypes on stress-related behavioral tests or divergent responses to antidepressant drugs. This paper reviews several of these rodent strains and illustrates the genetic strategies available to discover the long-sought susceptibility genes regulating these phenotypes.
Keywords: genetics, depression, antidepressant, rat, mouse, behavior, qtl
Current Pharmaceutical Design
Title: Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics
Volume: 11 Issue: 2
Author(s): James J. Crowley and Irwin Lucki
Affiliation:
Keywords: genetics, depression, antidepressant, rat, mouse, behavior, qtl
Abstract: Over the past several years, research has indicated that an individuals genetic makeup strongly influences not only their likelihood of developing depression, but also whether or not they will respond well to a particular antidepressant treatment. Identifying those genes regulating susceptibility to depression will increase our understanding of disease pathophysiology and direct the development of treatments that correct underlying neurobiological pathology related to stress-related psychiatric illnesses. Pharmacologically, the identification of genes regulating treatment response can lead to the design of novel pharmacological treatments and allow for more individualized, rational and successful drug treatments. Unfortunately, complex environmental and genetic mechanisms at play in depression and drug response make the discovery of susceptibility genes in humans quite difficult. Animal models may provide a more desirable system in which to discover susceptibility genes because environmental factors and tests can be regulated and more informative genetic methods can be used. Furthermore, a unique genetic opportunity exists with animal models of depression and antidepressant response because several rodent strains have been identified, or selectively bred, that display exaggerated depressive phenotypes on stress-related behavioral tests or divergent responses to antidepressant drugs. This paper reviews several of these rodent strains and illustrates the genetic strategies available to discover the long-sought susceptibility genes regulating these phenotypes.
Export Options
About this article
Cite this article as:
Crowley J. James and Lucki Irwin, Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382278
DOI https://dx.doi.org/10.2174/1381612053382278 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Approaches to Endothelin Receptor Antagonist-Bosentan
Letters in Organic Chemistry A Variant in the Endoglin Gene is Associated with the Development of Sporadic Intracranial Aneurysms
Current Neurovascular Research Canonical Wnt/Beta-Catenin Signaling Network as Emerging Signaling Cascade for Therapeutic Intervention in Chronic Renal Disease
Current Drug Targets Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Inhibition of Adipogenesis by Thiourea Derivatives
Medicinal Chemistry Management of Obesity in Pregnancy
Current Women`s Health Reviews Human Microdialysis
Current Pharmaceutical Biotechnology Novel Role of NPC1L1 in the Regulation of Hepatic Metabolism: Potential Contribution of Ezetimibe in NAFLD/NASH Treatment
Current Vascular Pharmacology Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design The Blockade of Renin-Angiotensin-Aldosterone System in Hemodialysis Patients to Control Hypertension and Prevent Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Fenoldopam in Cardiovascular Surgery: A Review
Vascular Disease Prevention (Discontinued) Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders Editorial [Inflammation and Atherosclerosis: Recent Insights and Future Perspectives]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry